Stand Up to Sarcoma: Raising Awareness This July

Florence G. Cepedoza, MD

This July, we stand united for Sarcoma Awareness Month a time to ignite hope, amplify voices, and fight for breakthroughs against these rare but relentless cancers. 

To every warrior in the battle, every caregiver holding steady hands, and every researcher chasing cures, your courage is changing the story of sarcoma.

Where there was once uncertainty, we now see growing hope in targeted therapies, improved diagnostics, and the unwavering spirit of this community.

OVERVIEW

Soft tissue sarcomas (STS) are aggressive cancers that develop from mesodermal tissues such as fat, muscle (both smooth and skeletal), blood vessels, and connective tissue. 

Some STS tumors, like those originating from nerve sheaths, actually stem from ectodermal tissue rather than mesoderm. Around 11,000 new STS cases are diagnosed annually, accounting for roughly 1% of all cancers, with a slightly higher incidence in males. These tumors result in approximately 3,900 deaths each year. 

While STS is generally rare across all age groups, it ranks as the third most common solid tumor in children, making up about 15% of pediatric cancers. 

Roughly half of all soft tissue sarcomas (STS) develop in the extremities, while about one-third originate in the abdomen, pelvis, or retroperitoneum. 

When STS metastasizes, the most common site of spread for extremity tumors is the lungs, whereas retroperitoneal sarcomas tend to recur locally or regionally rather than distantly.

  • CAUSES
  • While most sarcomas occur sporadically without identifiable causes, several risk factors have been established. Chemical exposures like vinyl chloride and thorium dioxide are linked to hepatic angiosarcomas, while chronic lymphedema (Stewart-Treves syndrome) predisposes to angiosarcoma development. Radiation exposure, both therapeutic and environmental, can induce sarcomas – particularly angiosarcoma and pleomorphic sarcoma – typically emerging about 10 years post-exposure within the treated area.
  • Genetic factors significantly contribute to sarcoma pathogenesis. TP53 gene mutations increases risk for soft tissue sarcomas and osteosarcomas, while NF1 gene mutations carries a 15% risk of malignant peripheral nerve sheath tumors and elevated GIST risk. APC gene mutations is associated with desmoid tumors. Gene fusions like SS18-SSX define synovial sarcoma, while amplifications such as MDM2/CDK4 on chromosome 12 characterize well-differentiated and dedifferentiated liposarcomas. These genetic alterations provide both diagnostic markers and potential therapeutic targets.
  • DIAGNOSIS
  • Sarcoma diagnosis requires a multimodal approach. Physicians begin with a thorough physical exam and symptom evaluation, followed by imaging studies such as X-rays, CT, MRI, or PET scans to assess tumor location and possible metastasis. The definitive diagnosis relies on a biopsy, where pathologists analyze tissue samples to identify the sarcoma subtype and grade. This comprehensive evaluation helps guide treatment planning and prognosis

TREATMENT

Surgery is the primary curative treatment for STS, requiring wide or radical resections to achieve negative margins. The tumor must be removed en bloc with a margin of healthy tissue to eliminate microscopic extensions beyond the pseudocapsule. 

The necessary resection extent and margin adequacy depend on factors such as tumor histology and anatomical barriers (fascia, periosteum, or epineurium).

Due to the complexity of STS management, evaluation at a specialized sarcoma center is essential. A multidisciplinary team—including surgical, medical, and radiation oncologists—determines whether neoadjuvant (Radiation Therapy) or adjuvant therapy (Radiation or Chentherapy) is indicated. Additionally, expert pathologic review is critical, as up to 25% of sarcomas are initially misclassified, with 15% having clinically significant errors affecting treatment. 

Complex cases often require collaboration with plastic, vascular, thoracic, or urologic surgeons for optimal outcomes.

PROGNOSIS

Prognosis for sarcoma patients correlates strongly with disease progression at diagnosis. For localized tumors confined to the primary site, approximately 81% of patients survive five years post-diagnosis. 

When the cancer involves regional lymph nodes or nearby tissues, this rate declines to 56%. The most significant survival challenge occurs with metastatic disease, where only 15% of patients reach the five-year milestone. 

These statistics underscore the critical importance of early detection and intervention in improving sarcoma outcomes.

MESSAGE OF HOPE

To you who are facing sarcoma this diagnosis may feel like an impossible storm, but even the fiercest storms have breaks of sunlight. You are stronger than you realize, more resilient than you feel in your hardest moments, and far from alone in this fight.

  • Sarcoma may be rare, but hope is not. Every day, researchers are uncovering new treatments, refining therapies, and rewriting what’s possible. Your journey is part of that progress. The courage you show whether sitting through another round of treatment, facing a scan with a deep breath, or simply getting out of bed on a tough day fuels the hope that one day, no one will have to fight this battle.